Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2013

View Archived Issues

Downregulated microRNAs appear to be biomarkers of primary biliary cirrhosis

Chitotriosidase-1 activity is elevated in patients with hepatocellular carcinoma

Coadministration of long-acting GSK-744 and rilpivirine found feasible

Data reported from clinical trials of ibrutinib for the treatment of hematological cancers

GAPVAC consortium to develop biomarker-guided actively personalized vaccines for glioblastoma

SK Biopharmaceuticals and AriBio enter strategic alliance

Transgene licenses anticancer immunotherapy to Ascend Biopharmaceuticals

First-in-human data on MLN-0264 in advanced gastrointestinal cancer reported

BioAlliance Pharma receives grant from bpifrance

Preclinical data confirm potential of nomethiazoles in Alzheimer's disease

First clinical study of AZD-8186 planned

Phase II trial of AQX-1125 in interstitial cystitis/bladder pain syndrome is under way

GlaxoSmithKline patents LDH-A inhibitors

Roche divulges new compounds for hepatitis C

Aragon Pharmaceuticals describes novel estrogen receptor-alpha modulators

National Health Research Institutes reports development of SGLT2 inhibitors

Lucentis approved in E.U. for myopic choroidal neovascularization

Onglyza set for launch in Japan

Pharmaxis and University of Sydney receive Australian Research Council grants

Shin Nippon Biomedical Laboratories and Retina Institute Japan enter business collaboration

U.S. researchers report novel compounds for influenza

Evotec and Boehringer Ingelheim alliance pain molecule to enter preclinical development

Galapagos receives grant from Flemish government for psoriasis research

BioInvent to receive milestone payment for n-CoDeR antibody program

Cha Bio&Diostech files Korean IND for PLX-PAD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...